Literature DB >> 30274623

Nonproliferative Forms of Lupus Nephritis: An Overview.

Andrew S Bomback1.   

Abstract

Most of the attention paid to lupus nephritis, in the medical literature and in clinical trials, has primarily focused on proliferative forms of lupus nephritis (class III and IV lesions), but with lower thresholds to biopsy and rebiopsy patients with lupus, clinicians are encountering more cases with purely mesangial disease (class I and II) or membranous nephropathy patterns (class V). These lesions often will be associated with milder disease courses but still require dedicated follow-up by a nephrologist and focused therapeutic strategies that, at times, will include immunosuppression.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lupus; Lupus nephritis; Nephrotic syndrome; Podoctyopathy

Mesh:

Year:  2018        PMID: 30274623     DOI: 10.1016/j.rdc.2018.06.003

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  3 in total

Review 1.  Update on Management of Cardiovascular Diseases in Women.

Authors:  Fabiana Lucà; Maurizio Giuseppe Abrignani; Iris Parrini; Stefania Angela Di Fusco; Simona Giubilato; Carmelo Massimiliano Rao; Laura Piccioni; Laura Cipolletta; Bruno Passaretti; Francesco Giallauria; Angelo Leone; Giuseppina Maura Francese; Carmine Riccio; Sandro Gelsomino; Furio Colivicchi; Michele Massimo Gulizia
Journal:  J Clin Med       Date:  2022-02-22       Impact factor: 4.241

2.  Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience.

Authors:  Emine Duran; Tolga Yıldırım; Arzu Taghiyeva; Emre Bilgin; Mustafa Arıcı; Emine Arzu Sağlam; Seza Özen; Meral Üner; Yunus Erdem; Umut Kalyoncu; Ali Ihsan Ertenli
Journal:  Lupus       Date:  2022-06-03       Impact factor: 2.858

Review 3.  Autoimmune Disease-Associated Hypertension.

Authors:  Victoria L Wolf; Michael J Ryan
Journal:  Curr Hypertens Rep       Date:  2019-02-02       Impact factor: 5.369

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.